Товары в корзине
Товары в корзине
Корзина пуста
Каталог лекарства Индии
Бесплатный звонок по России
Заказать звонок
Режим работы:
Пн-Пт 9:00—23:00;
Сб-Вс 10:00-20:00
0 В корзине Пусто 0 $
Товары в корзине
Корзина пуста

Plamumab (Adalimumab)

Plamumab (Adalimumab)
Cipla Ltd.

Plamumab consist of Adalimumab, exist as anti-inflammatory agent. Plamumab categorized as; Anti-inflammatory TNF inhibitors Biologic medication Immuno suppressive agent Plamumab is involved in the treatment of auto immune disease like rheumatoid arthritis.

Действующее вещество: Adalimumab
0 $
В избранное
В сравнение


Adalimumab is belonging to the class of tumor necrosis factor inhibitor, anti-inflammatory, or biologic drug. Plamumab has 40mg of Adalimumab which is human IgG1monoclonal antibody especially for tumor necrosis factor TNF

Plamumab 40mg/0.8ml containing an active ingredient Adalimumab is a FDA product involved in the therapy of rheumatoid arthritis, chronic plaque psoriasis, crohn’s disease, Ankylosing spondylitis, psoriatic arthritis & polyarticular juvenile idiopathic arthritis.


Plamumab consist of Adalimumab, exist as anti-inflammatory agent. Plamumab categorized as; Anti-inflammatory TNF inhibitors Biologic medication Immuno suppressive agent Plamumab is involved in the treatment of auto immune disease like rheumatoid arthritis.

In rheumatoid arthritis RA:
Plamumab is used to diminish the manifestation related to rheumatoid arthritis in adults, it also exhibits effect in serious polyarticular juvenile idiopathic arthritis with the age of 4 years or older. In this condition, Plamumab is used in combination with methotrexate.

In psoriasis arthritis PA:
Plamumab is used in psoriasis arthritis

In Ankylosing spondylitis AS:
Plamumab is used to reduce the syndrome of AS Various conditions like crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and juvenile idiopathic arthritis.


Tumor necrosis factor is a naturally arising cytokine, which involved in natural inflammatory and immune reaction. Increased level of tumor necrosis factor which is occurs in synovial fluid of rheumatoid arthritis patients. This elevation level leads to cause pathological inflammation and joint eradication.

Plamumab contains Adalimumab exhibits action by definitely binds to TNF-alpha and involved in blockade of inter communication of TNF alpha with its receptors like p55 & p75 cell surface receptors. Plamumab also sophisticated in lyses of surface TNF disclose cells in vitro in the presence of completion.


The peak plasma concentration time of Plamumab is occurs at 131 ± 56 hours and maximum serum concentration is 4.7 ± 1.6mcg/ml The mean bioavailability of Plamumab is reaches at 64% The volume of distribution is 4.7 to 6.0L

The systemic clearance of Adalimumab is relatively occurs as 12ml/hr The mean terminal half life period of Adalimumab is relatively occurs as 2 weeks ranging from 10 to 20 days



In RA, PA, & AS
The usual recommended dosage of Plamumab in these conditions, 40mg should be administered for every other week through subcutaneously. Other medicines like methotrexate, NSAIDS, glucocorticoid, salicylates, analgesics, or DMARDs may be carrying out during the therapy with Exemptia. In some patients, methotrexate is not used for combination. In this condition the dosage frequency of Plamumab is elevates to 40mg for every week.

In juvenile idiopathic arthritis
The usual dose of Plamumab is recommended for the age of 4 to 17 years with polyarticular JIA is calculated on the basis of body weight of the patients. Methotrexate, NSAIDS, glucocorticoid, salicylates or analgesics may be used in combination. In 10kg to less than 15kg: 10mg dose should be used In 15 kg to <30kg: 20mg of dose for every other week ≥30kg: 40mg of dose for every other week

In adult crohn’s
In this conditions, the recommended dosage of Plamumab is 160mg starting at day 1 (administered as four 40mg in a day or two 40mg per day for two successive days) proceeding with 80mg two weeks later (day 15). After two weeks, day 29 starts with continuance dose of 40mg every other week. Aminosalicylates, corticosteroids, or Immuno modulatory agents may be used during the therapy.

For pediatrics
6 years & older: 17kg to less than 40kg: The initial dose is 80mg given subcutaneous on day 1 followed by 40mg two weeks later, then 20mg SC every other week 40kg or greater: 160mg of Plamumab given subcutaneous on day 1, respectively 80mg SC for two weeks later, then 40mg SC every other week.

In ulcerative colitis
The recommended dosage of Plamumab is 160mg starting at day 1 (administered as four 40mg in a day or two 40mg per day for two successive days) proceeding with 80mg two weeks later (day 15). After two weeks, day 29 starts with continuance dose of 40mg every other week.

Plaque psoriasis
The recommended dosage of Plamumab is starting with 80mg, which is followed by 40mg for every other week, initiate one week after the initial dose

How to take Exemptia
Plamumab is a prefilled syringe, single use. Plamumab is administered through subcutaneous; with maintenance therapy at every week


Severe infections Malignancies, Erythema, Itching, Hemorrhage, Pain, swelling, Rash, Pneumonia, Tuberculosis, Lupus like syndrome, Sinusitis, Flu like syndrome, Respiratory tract infection, Abdominal pain, Nausea, Hypercholesterolemia, Hyperlipidaemia, Hematuria, Elevation of alkaline phosphatase, Injection site pain, Headache, Back pain, Hypertension, Thrombocytopenia, Anaphylaxis, Angioneurotic edema, Interstitial lung disease like pulmonary fibrosis, Cutaneous vasculitis, psoriasis, Erythema multiforme, Systemic vasculitis


To reduce the serious infections, avoid concomitant use of Plamumab with methotrexate, Anakinra etc Before starting the therapy, patient should be examine whether presence or absence of tuberculosis in active or latent stage. Plamumab therapy should not be recommended for the patients who are infected with active tuberculosis.

Risk takes into consideration while starting the therapy;
1. Severe or frequent infection
2. Patient exposed to tuberculosis
3. With the history of an opportunistic infection
4. With viral, fungal or bacterial infections

Patients should be frequently monitored, the signs and manifestation of tuberculosis The exposure and advantages of TNF-inhibitor therapy including Plamumab should be taken into consideration, before initiation of therapy. To reduce the risk of non-melanoma skin cancer or other malignancy In pediatric patients, Hepatosplenic T-cell lymphoma occurs during the TNF blocking therapy, this may occur due to combination of TNF blocker with other immunosuppressant Post marketing hypersensitivity reactions occurs like anaphylaxis, angioneurotic edema and other allergic conditions may occur. In this condition Plamumab should be discontinue and provide alternative medicine.

HBV reactivation occurs
Neurological reactions
Hematological reactions

While using with anakinra causes severe adverse reaction related to anakinra, avoid this concomitant Autoimmunity occurs during the therapy with Plamumab , lupus like syndrome occurs Immunizations, concurrent usage of Plamumab with live vaccine should be avoided While using abatacept with Plamumab causes serious infections, use Plamumab alone.


During the therapy with Plamumab , some serious infections may occur; Increased exposure of infections
Active tuberculosis
Invasive fungal infections like histoplasmosis, coccidioidomycosis, candidiasis, blastomycosis etc.
Viral and bacterial infections
Lymphomas and other malignancy
Hepatosplenic T-cell lymphoma


If Adalimumab combines with anakinra (interleukin 1 antagonist), or other TNF blocking agents may have increased the risk of adverse effects like neutropenia. Avoid the combination of Plamumab with Anakinra. Plamumab increase the adverse effects of Anakinra Live vaccines should not be concomitant during the therapy using with Plamumab In rheumatoid arthritis, Plamumab is combined with methotrexate causes depleting the apparent clearance of Exemptia


No contraindication occurs in the therapy. Some anaphylactic reactions may occur, if patients are contraindicated to the component present in the product Plamumab Severe infection like sepsis, tuberculosis occurs Moderate to serious heart failure occurs.


Pregnancy category: C Plamumab should not be recommended in pregnancy condition; placental transformation is applicable Plamumab used if it is necessary only getting advice from medical practitioner


Breast feeding should not be recommended


Plamumab prefilled syringe should be stored at refrigerator condition with the range of 2°C to 8°C (36°F to 46°F). Do not freeze; protect from light Plamumab should be store in an original carton until the time of administration. On travelling mode: Plamumab should be stored at room temperature at 25°C up to the period of 14 days, must protect from light. If Plamumab is not used within 14 days, it should be discarded.


After acquiring over dosage of Plamumab , the manifestation is monitored frequently. The suitable treatment should be provided for the over dosage of Plamumab immediately.


Plamumab is an Anti-rheumatoid agent, used cautiously If patient fail to take the dose of Plamumab must consult with medical adviser and follow the instructions On the other hand, the missed dose should be avoided and maintain the regular dosing schedule.

Plamumab (Adalimumab)
Добавить комментарий

Пока нет комментариев

Оплата производится после оформления заказа, оплата производится в банке по счёт фактуре на счёт компании в Индию. Если вы из России и испытываете какие-либо либо трудности с оплатой заказа, предоставим возможность перевода с карты на карту. Мы настоятельно рекомендуем вам поговорить со своим лечащим врачом о вашем конкретном заболевании и методах лечения перед тем как купить Plamumab из Индии.
Доставка осуществляется исключительно из Индии на адрес клиента, доставка Plamumab в пределах 15ти дней с момента получения трек номера посылки. Перед тем как купить Plamumab от компании Cipla Ltd. настоятельно рекомендуем проконсультироваться с вашим лечащим врачом по поводу приёма Plamumab.
Мы используем файлы cookie, чтобы сайт был лучше для вас! Примечание. Мы настоятельно рекомендуем вам поговорить со своим врачом о вашем конкретном заболевании и методах лечения.